Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 6794 (miR-6794 or MIR6794) is a microRNA—a small, non-coding RNA molecule involved in post-transcriptional regulation of gene expression[2]. It functions as a suppressor of metastasis in pancreatic cancer by downregulating genes such as RBBP4, thereby inhibiting cell invasion, migration, and EMT signaling[1]. Low expression levels of miR-6794-3p correlate with poor patient survival and increased cancer metastasis. The expression of miR-6794-3p can be silenced via promoter hypermethylation, which may be reversed by treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine[1]. MiR-6794 has shown value as both a prognostic biomarker and a potential therapeutic target in pancreatic cancer.
Mimic or overexpression results in suppression of target gene expression (e.g., RBBP4). Inhibition results in increased target gene expression (e.g., RBBP4, BCAT1, etc.). Indirect inhibition of histone H3 methylation via RBBP4 downregulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 6794 (miR-6794 (or MIR6794)).